Related references
Note: Only part of the references are listed.REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY Twelve-Month Results From the LUMINOUS Study
Adrian Koh et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Impact of intravitreal aflibercept dosing regimens in treatment-naive patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
Michel Weber et al.
BMC OPHTHALMOLOGY (2020)
Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients A Real-World Analysis of 49 485 Eyes
Thomas A. Ciulla et al.
OPHTHALMOLOGY RETINA (2020)
Projection of Long-Term Visual Acuity Outcomes Based on Initial Treatment Response in Neovascular Age-Related Macular Degeneration
Vuong Nguyen et al.
OPHTHALMOLOGY (2019)
Effectiveness and safety of intravitreal aflibercept in patients with wet age-related macular degeneration treated in routine clinical practices across France: 12-month outcomes of the RAINBOW study
Michel Weber et al.
BMJ OPEN OPHTHALMOLOGY (2019)
Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review
Saira Khanna et al.
BMJ OPEN OPHTHALMOLOGY (2019)
The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis
Mali Okada et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry
Prethy Rao et al.
OPHTHALMOLOGY (2018)
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration Results with Ranibizumab from the TREND Study
Rufino Silva et al.
OPHTHALMOLOGY (2018)
One-Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age-Related Macular Degeneration: A Meta-Analysis
Michael Y. Guo et al.
PHARMACOTHERAPY (2018)
TWO YEAR OUTCOMES OF TREAT AND EXTEND INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Daniel Barthelmes et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)
Age-related macular degeneration
Paul Mitchell et al.
LANCET (2018)
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Maria Eleftheriadou et al.
OPHTHALMOLOGY AND THERAPY (2018)
Outcome of 5-Year Treatment of Neovascular Age-Aelated Macular Degeneration With Intravitreal Anti-VEGF Using Treat and Extend Regimen
Polona Jaki Mekjavic et al.
FRONTIERS IN MEDICINE (2018)
Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial
Charles C. Wykoff et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2018)
Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy
Devy Deliyanti et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
Shinichi Sakamoto et al.
CLINICAL OPHTHALMOLOGY (2018)
Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study
Katja Hatz et al.
ACTA OPHTHALMOLOGICA (2017)
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
Thomas Wecker et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
The impact of typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy on vision-related quality of life in Asian patients
Eva K. Fenwick et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
A modified treat-and-extend regimen of aflibercept for treatment-na⟨ve patients with neovascular age-related macular degeneration
Masayuki Ohnaka et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age related macular degeneration
H. Almuhtaseb et al.
EYE (2017)
Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group
H. Almuhtaseb et al.
EYE (2017)
Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases
Paolo Lanzetta et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Two-Year Outcomes of a Treat-and-Extend Regimen Using Intravitreal Aflibercept Injections for Typical Age-Related Macular Degeneration
Arisa Ito et al.
OPHTHALMOLOGICA (2017)
One-Year Outcomes of a Treat-and-Extend Regimen of Aflibercept for Exudative Age-Related Macular Degeneration
Akiko Yamamoto et al.
OPHTHALMOLOGICA (2017)
Prevalence of Age-Related Macular Degeneration in Europe
Johanna M. Colijn et al.
OPHTHALMOLOGY (2017)
24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting
Athanasios Vardarinos et al.
BMC OPHTHALMOLOGY (2017)
UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice
Aaron Y. Lee et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2017)
Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS™ study
E. Souied et al.
ACTA OPHTHALMOLOGICA (2017)
Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-related Macular Degeneration: A Prospective Clinical Trial
Francis Char Decroos et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2017)
Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration 2-Year Results of the TREX-AMD Study
Charles C. Wykoff et al.
OPHTHALMOLOGY RETINA (2017)
Ranibizumab for the treatment of wet AMD: a summary of real-world studies
V. Chong
EYE (2016)
Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy
F. Ricci et al.
EYE (2016)
Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study
F. G. Holz et al.
EYE (2016)
First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration
James S. Talks et al.
OPHTHALMOLOGY (2016)
METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Leah N. Kim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION 5-Year Results of The Pan-American Collaborative Retina Study Group
J. Fernando Arevalo et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY
Ryan N. Vogel et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
The emotional and physical impact of wet age-related macular degeneration: findings from the wAMD Patient and Caregiver Survey
Monica Varano et al.
CLINICAL OPHTHALMOLOGY (2016)
Treatment Outcomes After 3 Years in Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen
Nadim Rayess et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)
Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing
Shelagh M. Szabo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2015)
Two-Year Outcomes of Treat and Extend Intravitreal Therapy for Neovascular Age-Related Macular Degeneration
Jennifer J. Arnold et al.
OPHTHALMOLOGY (2015)
Bevacizumab treatment for neovascular age-related macular degeneration in the setting of a clinic: real life long-term outcome
Gala Beykin et al.
BMC OPHTHALMOLOGY (2015)
Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab
Archana Airody et al.
ACTA OPHTHALMOLOGICA (2015)
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis
Martin K. Schmid et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
Meidong Zhu et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2015)
Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
Ursula Schmidt-Erfurth et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010
Rupert R. A. Bourne et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2014)
Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration Ninety-Six-Week Results of the VIEW Studies
Ursula Schmidt-Erfurth et al.
OPHTHALMOLOGY (2014)
ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A Treat-and-Extend Protocol Over 2 Years
Farshad Abedi et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The Importance of Baseline Characteristics
Ryan B. Rush et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2014)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
A 4-Year Longitudinal Study of 555 Patients Treated with Ranibizumab for Neovascular Age-related Macular Degeneration
Annette Rasmussen et al.
OPHTHALMOLOGY (2013)
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Brandon G. Busbee et al.
OPHTHALMOLOGY (2013)
The SECURE Study Long-Term Safety of Ranibizumab 0.5 mg in Neovascular Age-related Macular Degeneration
Rufino Silva et al.
OPHTHALMOLOGY (2013)
Bevacizumab for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen: Clinical and Economic Impact
Gary Shienbaum et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Age-related macular degeneration
Laurence S. Lim et al.
LANCET (2012)
HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Michael A. Singer et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
ONE-YEAR RESULTS OF A FLEXIBLE REGIMEN WITH RANIBIZUMAB THERAPY IN MACULAR DEGENERATION Relationship with the Number of Injections
Luis Arias et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED A Comparative Retrospective Study of Ranibizumab in Exudative Age-Related Macular Degeneration
Hassiba Oubraham et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)
The Prevalence of Age-Related Macular Degeneration in Asians A Systematic Review and Meta-Analysis
Ryo Kawasaki et al.
OPHTHALMOLOGY (2010)
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact
Omesh P. Gupta et al.
OPHTHALMOLOGY (2010)
The natural history and prognosis of neovascular age-related macular degeneration
Tien Wong et al.
OPHTHALMOLOGY (2008)
Clinical update: new treatments for age-related macular degeneration
Tien Y. Wong et al.
LANCET (2007)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Impact of age related macular degeneration on quality of life
JB Hassell et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2006)
Pegaptanib for neovascular age-related macular degeneration
ES Gragoudas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization
K Spilsbury et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
